Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

665 ARTÍCULOS , VIENDO DEL 481 AL 495

Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS)

Cho H, Mundada NS, Apostolova LG, Carrillo MC, Shankar R, Amuiri AN, Zeltzer E, Windon CC, Soleimani-Meigooni DN, Tanner JA, Heath CL, Lesman-Segev OH, Aisen P, Eloyan A, Lee HS, Hammers DB, Kirby K, Dage JL, Fagan A, Foroud T, Grinberg LT, Jack CR, Kramer J, Kukull WA, Murray ME, Nudelman K, Toga A, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu J, Mendez M, Musiek E, Onyike CU, Riddle M, Rogalski EJ, Salloway S, Sha S, Turner RS, Wingo TS, Wolk DA, Koeppe R, Iaccarino L, Dickerson BC, La Joie R, Rabinovici GD; LEADS Consortium.

Alzheimers Dement. 2023 Nov;19 Suppl 9(Suppl 9):S98-S114. doi: 10.1002/alz.13453. Epub 2023 Sep 10.

Unravelling of molecular biomarkers in synaptic plasticity of Alzheimer's disease: Critical role of the restoration of neuronal circuits

Pinky, Neha, Ali M, Tiwari P, Alam MM, Hattiwale HM, Jamal A, Parvez S.

Ageing Res Rev. 2023 Nov;91:102069. doi: 10.1016/j.arr.2023.102069. Epub 2023 Sep 9.

Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification

Cummings JL, Osse AML, Kinney JW.

Drugs. 2023 Oct;83(15):1387-1408. doi: 10.1007/s40265-023-01938-w. Epub 2023 Sep 20.

Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants

Dubois B, von Arnim CAF, Burnie N, Bozeat S, Cummings J.

Alzheimers Res Ther. 2023 Oct 13;15(1):175. doi: 10.1186/s13195-023-01314-6.

Accelerating Alzheimer's therapeutic development: The past and future of clinical trials

Boxer AL, Sperling R.

Cell. 2023 Oct 26;186(22):4757-4772. doi: 10.1016/j.cell.2023.09.023. Epub 2023 Oct 16.

ASURE Clinical Trial Protocol: A Randomized, Placebo-Controlled, Proof-of-Concept Study Aiming to Evaluate Safety and Target Engagement following Administration of TW001 in Early Alzheimer's Disease Patients

Oosthoek M, Lili A, Almeida A, van Loosbroek O, van der Geest R, de Greef-van der Sandt I, van Bokhoven P, Sikkes SAM, Teunissen CE, Vijverberg EGB.

J Prev Alzheimers Dis. 2023;10(4):669-674. doi: 10.14283/jpad.2023.107.

The Critical Role of Biomarkers for Drug Development Targeting the Biology of Aging

Owen M, Bose N, Nisenbaum L, Partrick KA, Fillit HM.

J Prev Alzheimers Dis. 2023;10(4):729-742. doi: 10.14283/jpad.2023.111.

Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial

Edwards AL, Collins JA, Junge C, Kordasiewicz H, Mignon L, Wu S, Li Y, Lin L, DuBois J, Hutchison RM, Ziogas N, Shulman M, Martarello L, Graham D, Lane R, Budd Haeberlein S, Beaver J.

JAMA Neurol. 2023 Dec 1;80(12):1344-1352. doi: 10.1001/jamaneurol.2023.3861.

Potential Retinal Biomarkers in Alzheimer's Disease

García-Bermúdez MY, Vohra R, Freude K, Wijngaarden PV, Martin K, Thomsen MS, Aldana BI, Kolko M.

Int J Mol Sci. 2023 Oct 31;24(21):15834. doi: 10.3390/ijms242115834.

The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials

Wu W, Ji Y, Wang Z, Wu X, Li J, Gu F, Chen Z, Wang Z.

Eur J Med Res. 2023 Nov 28;28(1):544. doi: 10.1186/s40001-023-01512-w.

Recent Insights on Glutamatergic Dysfunction in Alzheimer's Disease and Therapeutic Implications

Pinky PD, Pfitzer JC, Senfeld J, Hong H, Bhattacharya S, Suppiramaniam V, Qureshi I, Reed MN.

Neuroscientist. 2023 Aug;29(4):461-471. doi: 10.1177/10738584211069897. Epub 2022 Jan 25.

Role of aluminum exposure on Alzheimer's disease and related glycogen synthase kinase pathway

Sanajou S, Erkekoğlu P, Şahin G, Baydar T.

Drug Chem Toxicol. 2023 May;46(3):510-522. doi: 10.1080/01480545.2022.2065291. Epub 2022 Apr 21.

Therapeutic role of curcumin in adult neurogenesis for management of psychiatric and neurological disorders: a scientometric study to an in-depth review

Ma W, Xu D, Zhao L, Yuan M, Cui YL, Li Y.

Crit Rev Food Sci Nutr. 2023;63(28):9379-9391. doi: 10.1080/10408398.2022.2067827. Epub 2022 Apr 28.

Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease

Aillaud I, Funke SA.

Cell Mol Neurobiol. 2023 Apr;43(3):951-961. doi: 10.1007/s10571-022-01230-7. Epub 2022 May 21.

The therapeutic potential of the neuroactive peptides of soluble amyloid precursor protein-alpha in Alzheimer's disease and related neurological disorders

Mockett BG, Ryan MM.

Semin Cell Dev Biol. 2023 Apr;139:93-101. doi: 10.1016/j.semcdb.2022.05.014. Epub 2022 May 30.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias